Progression of chronic kidney disease (CKD) in children leads to end stage renal disease (ESRD), which is associated with mortality rates 30-150 times higher than the general pediatric population. The traditional biomarkers, serum creatinine and proteinuria, are used to predict progression of CKD in clinical trials even though both correlate poorly with the progression of CKD and the response to interventions.
We aim to identify the optimal combination of novel biomarkers which best predict progression of CKD in children. We plan to measure urine and blood biomarkers of kidney injury, inflammation, repair, and fibrosis from the samples of the children enrolled in the CKD in Children (CKiD) cohort and Assessment, Serial Evaluation, and Subsequent Sequelae in AKI (ASSESS-AKI) cohort studies. Using biomarkers that represent the multifactoral pathophysiology of CKD progression, we will be able to quantify the spectrum of kidney injury.
Susan L. Furth, MD, PhD
Children's Hospital of Philadelphia
Prasad Devarajan, MD
Cincinnati Children's Hospital
Michael Zappitelli, MD, M.Sc.
The Hospital for Sick Children (Toronto, ON)